# **Anti-CD21** [BU81]

Catalogue number: 153225

Sub-type: Images:

#### Contributor

**Inventor:** Margaret Goodall

Institute: University of Birmingham

Images:

#### **Tool details**

#### \*FOR RESEARCH USE ONLY

Name: Anti-CD21 [BU81]

Alternate name: Complement receptor type 2; CR2; complement C3d receptor, C3DR, Epstein-Barr

ols.org

virus receptor

Class: Monoclonal

Conjugate: Unconjugated

Description: Cluster of differentiation 21 (CD21) is a protein encoded by the CR2 gene in humans. It is involved in the complement system and binds to iC3b (an inactive derivative of C3b). B cells are known to have CR2 receptors on their surfaces allowing the complement system to act in B-cell maturation and activation. Genetic variations are associated with susceptibility to systemic lupus erythematosus type 9 (SLEB9) which is a chronic autoimmune disease with an inflammatory, and often febrile multisystemic disorder of connective tissue characterized principally by involvement of the skin, joints, kidneys, and serosal membranes.

Purpose: Parental cell: Organism: Tissue: Model: Gender: Isotype: IgG1

Reactivity: Human

Selectivity: Host: Mouse

Immunogen: Folicual dentritic cells and germinal centre B cells

**Immunogen UNIPROT ID:** 

Sequence:

**Growth properties:** 

**Production details:** 

Formulation:

Recommended controls:

**Bacterial resistance:** Selectable markers: Additional notes:

## **Target details**

Target: CD21

#### **Target alternate names:**

Target background: Cluster of differentiation 21 (CD21) is a protein encoded by the CR2 gene in humans. It is involved in the complement system and binds to iC3b (an inactive derivative of C3b). B cells are known to have CR2 receptors on their surfaces allowing the complement system to act in Bcell maturation and activation. Genetic variations are associated with susceptibility to systemic lupus erythematosus type 9 (SLEB9) which is a chronic autoimmune disease with an inflammatory, and often Cancer febrile multisystemic disorder of connective tissue characterized principally by involvement of the skin, joints, kidneys, and serosal membranes.

#### Molecular weight:

Ic50:

## **Applications**

**Application: IHC Application notes:** 

## Handling

Format: Liquid

Concentration: 0.9-1.1mg/ml

Passage number: **Growth medium: Temperature: Atmosphere:** Volume:

Storage medium:

Storage buffer: PBS with 0.02% azide Storage conditions: -15° C to -25° C Shipping conditions: Shipping at 4° C

## **Related tools**

**Related tools:** 

## References

References: Leucocyte Typing VI, (1998): edited by T. Kishimoto, Garland Publishing, New York.; Ling et al. 1998. Clin Exp Immunol. 113(3):360-6. PMID: 9737663.; Ling et al. 1998. Clin Exp Immunol. 113(3):360-6. PMID: 9737663.; Buescher et al. 1991. Public Health Rep. 106(3):333-8. PMID: 1905057.

